| 1.2 0.03 (2.56%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.68  |
1-year : | 1.97 |
| Resists | First : | 1.44 |
Second : | 1.68 |
| Pivot price | 1.09 |
|||
| Supports | First : | 1.1 |
Second : | 0.89 |
| MAs | MA(5) : | 1.16  |
MA(20) : | 1.09 |
| MA(100) : | 1.64 |
MA(250) : | 1.42 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 78.7 |
D(3) : | 72.2 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 2.54 | Low : | 0.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CMMB ] has closed below upper band by 19.5%. Bollinger Bands are 25.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.26 - 1.27 | 1.27 - 1.27 |
| Low: | 1.19 - 1.19 | 1.19 - 1.2 |
| Close: | 1.19 - 1.2 | 1.2 - 1.21 |
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Mon, 21 Apr 2025
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences - TradingView
Mon, 21 Apr 2025
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences - Yahoo Finance
Mon, 21 Apr 2025
Groundbreaking PSC Treatment Data: Nebokitug Shows Promise in Multiple Clinical Trials - Key Findings Revealed - Stock Titan
Wed, 16 Apr 2025
Chemomab Announces New Medical and Clinical Appointments - markets.businessinsider.com
Tue, 15 Apr 2025
Chemomab Bolsters Medical Team as Revolutionary PSC Drug Advances Toward FDA - Stock Titan
Tue, 15 Apr 2025
Chemomab Therapeutics to Present at Upcoming Scientific Conferences - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 236 (M) |
| Held by Insiders | 15.9 (%) |
| Held by Institutions | 25.9 (%) |
| Shares Short | 270 (K) |
| Shares Short P.Month | 29 (K) |
| EPS | -0.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.1 % |
| Return on Equity (ttm) | -91.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.4 |
| PEG Ratio | 0 |
| Price to Book value | 1.66 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|